secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001104659-22-085661
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics appoints Alexandra MacLean, M.D. as CEO
-----------------------------------------------------------

- Alexandra MacLean, M.D., appointed CEO effective August 1, 2022.
- Dr. MacLean previously an Entrepreneur in Residence at Fortress Biotech (FBIO).
- She will receive an annual cash salary of $332,200; no employment agreement yet.
- David Jin ends interim CEO role, remains interim CFO and COO.
- No family relationships or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/tm2222416d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer